Asciminib hydrochloride - CAS 2119669-71-3

Asciminib hydrochloride is described as a "STAMP inhibitor, " specifically targeting the ABL myristoyl pocket, Asciminib hydrochloride, marketed as Scemblix, are applied in research in Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) by binding to the allosteric site of wild-type ABL N-terminus, which is myristoylated, whereas the ABL fusion protein lacks this domain, enabling selective modulation of oncogenic signaling pathways and serving as a targeted therapeutic tool in hematologic cancer research.

Bcr-Abl

Angiogenesis, Cytoskeletal Signaling, Tyrosine Kinase/Adaptors

2119595

0.9991

C20H19Cl2F2N5O3

486.3

C(NC1=CC=C(OC(Cl)(F)F)C=C1)(=O)C2=CC(=C(N=C2)N3CC[C@@H](O)C3)C=4C=CNN4.Cl

-20°C

Ice Packs

Small Compound